bluuebunny/crossref_metadata_2025_split huggingface dataset:
Physical Fitness and Fatness in Adolescents with Intellectual Disabilities
Authors: Salaun Laureline , Berthouze‐Aranda Sophie E. 
Published: February 2012

Background  This study investigated health‐related fitness in adolescents with intellectual disabilities and analysed the various performances in physical fitness tests according to degrees of obesity.Materials and Methods  Eighty‐seven French intellectual disabilities adolescents (14.24 ± 1.48 years) performed the EUROFIT physical fitness test battery. Height, weight and waist circumference were assessed, and BMI and waist‐to‐height ratio were calculated. ‘Bio‐impedancemetry’ evaluated body fat (BF) percentage.Results  Ninety‐four per cent of the adolescents completed the aerobic running test, 52% of which had low VO2max. Thirty‐seven per cent were obese (%BF), and 32% had excess visceral adipose tissue. Adolescents with the lowest cardiorespiratory fitness had the highest BF percentages (P < 0.001).Conclusions  Intellectual disabilities adolescents showed low physical fitness and high prevalence of obesity. Both could further worsen social participation and health status.
Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys
Authors: Ulu A , Appt SE , Morisseau C , Hwang SH , Jones PD , Rose TE , Dong H , Lango J , Yang J , Tsai HJ , Miyabe C , Fortenbach C , Adams MR , Hammock BD 
Published: February 2012

BACKGROUND AND PURPOSE Soluble epoxide hydrolase inhibitors (sEHIs) possess anti‐inflammatory, antiatherosclerotic, antihypertensive and analgesic properties. The pharmacokinetics (PK) and pharmacodynamics in terms of inhibitory potency of sEHIs were assessed in non‐human primates (NHPs). Development of a sEHI for use in NHPs will facilitate investigations on the role of sEH in numerous chronic inflammatory conditions.EXPERIMENTAL APPROACH PK parameters of 11 sEHIs in cynomolgus monkeys were determined after oral dosing with 0.3 mg·kg−1. Their physical properties and inhibitory potency in hepatic cytosol of cynomolgus monkeys were examined. Dose‐dependent effects of the two inhibitors 1‐trifluoromethoxyphenyl‐3‐(1‐propionylpiperidin‐4‐yl) urea (TPPU) and the related acetyl piperidine derivative, 1‐trifluoromethoxyphenyl‐3‐(1‐acetylpiperidin‐4‐yl) urea (TPAU), on natural blood eicosanoids, were determined.KEY RESULTS Among the inhibitors tested, TPPU and two 4‐(cyclohexyloxy) benzoic acid urea sEHIs displayed high plasma concentrations (>10 × IC50), when dosed orally at 0.3 mg·kg−1. Although the 4‐(cyclohexyloxy) benzoic acid ureas were more potent against monkey sEH than piperidyl ureas (TPAU and TPPU), the latter compounds showed higher plasma concentrations and more drug‐like properties. The Cmax increased with dose from 0.3 to 3 mg·kg−1 for TPPU and from 0.1 to 3 mg·kg−1 for TPAU, although it was not linear over this range of doses. As an indication of target engagement, ratios of linoleate epoxides to diols increased with TPPU administration.CONCLUSION AND IMPLICATIONS Our data indicate that TPPU is suitable for investigating sEH biology and the role of epoxide‐containing lipids in modulating inflammatory diseases in NHPs.
Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) study
Authors: Richman Sara , Gee Adrian P. , McKenna David H. , Traverse Jay H. , Henry Timothy D. , Fisk Diann , Pepine Carl J. , Bloom Jeannette , Willerson James T. , Prater Karen , Zhao David , Koç Jane Reese , Anwaruddin Saif , Taylor Doris A. , Cogle Christopher R. , Moyé Lemuel A. , Simari Robert D. , Skarlatos Sonia I. 
Published: February 2012

BACKGROUND: Cellular therapy studies are often conducted at multiple clinical sites to accrue larger patient numbers. In many cases this necessitates use of localized good manufacturing practices facilities to supply the cells. To assure consistent quality, oversight by a quality assurance group is advisable. In this study we report the findings of such a group established as part of the Cardiovascular Cell Therapy Research Network (CCTRN) studies involving use of autologous bone marrow mononuclear cells (ABMMCs) to treat myocardial infarction and heart failure.STUDY DESIGN AND METHODS: Factors affecting cell manufacturing time were studied in 269 patients enrolled on three CCTRN protocols using automated cell processing system (Sepax, Biosafe SA)‐separated ABMMCs. The cells were prepared at five good manufacturing practices cell processing facilities and delivered to local treatment sites or more distant satellite centers.RESULTS: Although the Sepax procedure takes only 90 minutes, the total time for processing was approximately 7 hours. Contributing to this were incoming testing and device preparation, release testing, patient randomization, and product delivery. The mean out‐of‐body time (OBT), which was to be less than 12 hours, averaged 9 hours. A detailed analysis of practices at each center revealed a variety of factors that contributed to this OBT.CONCLUSION: We conclude that rapid cell enrichment procedures may give a false impression of the time actually required to prepare a cellular therapy product for release and administration. Institutional procedures also differ and can contribute to delays; however, in aggregate it is possible to achieve an overall manufacturing and testing time that is similar at multiple facilities.
Platelet concentrates prepared after a 20‐ to 24‐hour hold of the whole blood at 22°C
Authors: Slichter Sherrill J. , Corson Jill , Jones Mary Kay , Christoffel Todd , Pellham Esther , Bolgiano Doug 
Published: February 2012

BACKGROUND: The Food and Drug Administration (FDA) requires that red blood cells must be refrigerated within 8 hours of whole blood collection. Longer storage of whole blood at 22°C before component preparation would have many advantages.STUDY DESIGN AND METHODS: Two methods of holding whole blood for 20 to 24 hours at room temperature were evaluated, refrigerated plates or a 23°C incubator. After extended whole blood storage, platelet (PLT) concentrates were prepared from PLT‐rich plasma on Day 1 postdonation, and the PLTs were stored for 6 more days. On Day 7 of PLT storage, blood was drawn from each subject to prepare fresh PLTs. The stored and fresh PLTs were radiolabeled and transfused into their donor.RESULTS: Eleven subjects' whole blood was stored using refrigerated butanediol plates (Compocool, Fresenius), and 10 using an incubator. Poststorage PLT recoveries averaged 47 ± 13% versus 53 ± 11% and survivals averaged 4.6 ± 1.7 days versus 4.7 ± 0.9 days for Compocool versus incubator storage, respectively (p = NS). With all results, poststorage PLT recoveries averaged 75 ± 10% of fresh and survivals 57 ± 13% of fresh; PLT recoveries met FDA guidelines for poststorage PLT viability but not survivals.CONCLUSION: Seven‐day poststorage PLT viability is comparable when whole blood is stored for 22 ± 2 hours at 22°C using either refrigerated plates or an incubator to maintain temperature before preparing PLT concentrates.
Adverse reactions, psychological factors, and their effect on donor retention in men and women
Authors: Veldhuizen Ingrid , Atsma Femke , van Dongen Anne , de Kort Wim 
Published: February 2012

BACKGROUND: This study investigates the effect of a vasovagal reaction (VVR) or needle reaction (NR) on the risk of stopping as a blood donor, taking into account variables from the Theory of Planned Behavior (TPB). Is stopping risk solely related to the adverse reaction itself, or do the TPB variables play a role as well? Emphasis is placed on possible sex differences.STUDY DESIGN AND METHODS: TPB variables were assessed within 12,051 whole blood donors. Also, donors reported the occurrence of adverse reactions during or after their last donation. Blood bank records were used to determine whether donors stopped donating within the next 2 years. Logistic regression analyses were performed to estimate the effect of self‐reported adverse reactions on stopping risk, adjusting for the TPB variables. Analyses were performed separately for both sexes.RESULTS: Men have a lower odds of reporting a NR or a VVR than women (odds ratio [OR] 0.34, 95% confidence interval [CI], 0.28‐0.43; and OR 0.26, 95% CI 0.19‐0.36, for NR and VVR, respectively). For both sexes, only a VVR was associated with stopping risk, which is higher in men (men, OR 3.95, 95% CI 2.19‐7.11; women, OR 1.78, 95% CI 1.35‐2.35). After adjusting for the TPB variables both ORs declined (men, OR 3.38, 95% CI 1.86‐6.15; women, OR 1.58, 95% CI 1.17‐2.14). Also, self‐efficacy and affective attitude are negatively associated with adverse reactions.CONCLUSION: Female donors report more VVRs than male donors, but male donors have a higher stopping risk after a VVR than female donors. Coping differences and possible reporting tendencies might play a role. For donor retention purposes, prevention and coping techniques should take sex differences into account.
Correlation of improved hepatitis B surface antigen detection limits with hepatitis B virus DNA nucleic acid test yield in blood donations
Authors: Martin Lynn A. , Stramer Susan L. , Kuhns Mary C. , Schlauder George G. 
Published: February 2012

BACKGROUND: This study provides data on the quantitative relationship between hepatitis B surface antigen (HBsAg; ng/mL) and hepatitis B virus (HBV) nucleic acid test (NAT; copies/mL) and addresses whether HBsAg assays with improved sensitivity would impact the detection of HBV‐positive samples from occult or early seroconversion window period infections.STUDY DESIGN AND METHODS: Plasma samples were tested with an HBsAg assay (PRISM, Abbott Laboratories; sensitivity, 0.08‐0.1 ng/mL) and with two HBsAg research prototype assays: HBsAg Prototype 1 (sensitivity, 0.032‐0.045 ng/mL) and HBsAg Prototype 2 (sensitivity, 0.009‐0.017 ng/mL); NAT assays were used to determine HBV DNA copy levels.RESULTS: Samples from 10 hepatitis B seroconversion panels covering the ramp‐up phase were utilized to examine the relationship between detection of HBsAg using improved assays and viral load using quantitative HBV DNA polymerase chain reaction. For these samples, detection at the HBsAg assay cutoff (sample‐to‐cutoff ratio, 1.0) corresponded to 206 copies/mL HBV DNA for the HBsAg Prototype 1 assay and 329 copies/mL for the PRISM HBsAg assay. Compared to the PRISM HBsAg and HBsAg Prototype 1 assays, the HBsAg Prototype 2 assay detected two additional samples of 32 HBV DNA–positive samples obtained from blood donors with occult HBV and one of seven from blood donors with early window period infections.CONCLUSION: Increased sensitivity HBsAg assays result in the detection of samples containing lower viral loads. Improvements in the analytic sensitivity of HBsAg prototype assays allow the detection of additional HBV DNA–positive samples from donors with window period or occult infections compared to PRISM HBsAg. Improved HBsAg assays should allow for incremental detection of HBV infection.
Long‐Term Safety and Effectiveness of Drug‐Eluting Stents Compared to Bare Metal Stents in ST Elevation Myocardial Infarction: Findings from the Guthrie Health Off‐Label Stent (GHOST) Registry
Authors: SATTUR SUDHAKAR , ORSHAW PAM , BOURA JUDY , HARJAI KISHORE J. 
Published: February 2012

Background:

Multiple randomized trials and observational studies have shown drug‐eluting stents (DES) to be safe and effective at 3‐year follow‐up in stent thrombosis (ST)‐segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). However, outcomes data beyond 3–4 years after DES implantation are sparse.
Methods:

We studied 554 STEMI patients who underwent successful PCI with either DES or bare metal stent (BMS). Primary study end‐points were time to occurrence of ST and the composite of death or myocardial infarction (MI). Secondary end‐points were time to occurrence of major adverse cardiac events (MACEs) and discrete events that comprise MACE (death, MI, and target vessel revascularization [TVR]). Outcomes of the DES and BMS groups were assessed by survival analysis and multivariable Cox regression.
Results:

There were 205 (37%) patients who received DES and 349 (63%) patients who received BMS. At a median follow‐up of 41.4 months after PCI, there were no differences in the unadjusted incidence of ST (ST, 3.4 vs. 4.3%, log‐rank P = 0.61) and MI (6.8% vs. 8%, P = 0.61) between DES versus BMS groups, respectively. However, DES implantation was associated with lower unadjusted incidence of death or MI (11% vs. 23.5%, P = 0.0002), MACE (16% vs. 34%, P < 0.0001), death (6.3% vs. 17%, P = 0.0004), and TVR (9.8% vs. 18%, P = 0.008) than BMS implantation. In multivariable analyses, DES implantation was associated with significantly lower incidence of MACE (adjusted HR = 0.47 [95% CI: 0.31–0.76], P = 0.0007) than BMS implantation.
Conclusion:

In our study of STEMI patients, DES implantation was safer than BMS implantation and was associated with lower MACE at long‐term follow‐up. (J Interven Cardiol 2012;25:118–125)
Evaluation of associative effects on ruminal digestion kinetics between pasture and grains using in vitro gas production method
Authors: CHO Aye Sandar , UEDA Koichiro , KONDO Seiji 
Published: February 2012

ABSTRACTIn vitro gas production (GP) method was used to investigate associative effects on ruminal digestion when grains (corn or barley) were supplemented to spring pasture and autumn pasture. Pasture (75%) was incubated with 25% corn or barley and gas production was monitored up to 96 h. After incubation, the residues were used to determine dry matter and organic matter digestibility (DMD and OMD). Gas production parameters were analyzed by applying a single exponential equation. Organic matter effective degradability (OMED) was determined from GP parameters and OMD. The positive associative effects on the rate of GP, DMD, OMD and OMED were observed when spring pasture was incubated with corn. However, similar effects were not observed in a barley mixture. However, for autumn pasture, both corn and barley mixtures showed positive associative effects on rate of GP, OMD and OMED. The results of this study indicated that supplementation of corn would be better than barley for spring pasture with high water‐soluble carbohydrate contents, whereas both grain supplementations were effective to obtain positive associative effects on the rate of GP and OMED for autumn pasture with high cell wall content.
Utilization of dietary urea nitrogen is stimulated by D‐mannitol feeding in rabbits
Authors: LI Xiao , MIN Xiao , XIAO Jin , KAWASAKI Kiyonori , OHTA Naoko , SAKAGUCHI Ei 
Published: February 2012

ABSTRACTThe effect of D‐mannitol as an indigestible sugar on apparent digestibility of nutrients, nitrogen (N) utilization and growth performance, have been investigated in growing rabbits fed a urea‐containing diet. In experiment 1, 40‐day‐old male rabbits were fed a commercial diet with urea 10 g/kg with added glucose or D‐mannitol 60 g/kg each. Thereafter, in experiment 2 the rabbits aged 55 days were fed a commercial diet with or without urea 10 g/kg. Feed restriction at 55 g/kg0.75/day was carried out in both experiments. Addition of D‐mannitol to the urea‐containing diet decreased urinary N excretion, which consequently increased N retention and ratios of retained N to consumed N or apparently absorbed N. Addition of urea alone to the diet increased daily N intake and urinary N excretion but did not affect N retention. Weight gain and feed efficiency were improved by D‐mannitol feeding, whereas feeding with urea alone did not affect these parameters. Utilization of dietary urea was enhanced in growing rabbits fed the urea‐containing diet with D‐mannitol, resulting in improvement of N retention and growth performance.
Characterization of heterotopic cell clusters in the hippocampus of the rat after prenatal treatment of methylazoxymethanol acetate
Authors: Imai Hideaki , Yamamoto Tatsuro , Terashima Toshio , Sugioka Kozo 
Published: February 2012

AbstractPrenatal exposure of methylazoxymethanol acetate, a DNA methylating agent, to pregnant rats on embryonic day 15 is known to produce hippocampal malformation and laminar disorganization of the cerebral cortex. However, there are few studies to demonstrate developmental processes of abnormal structures in the hippocampus. In the present study, we examined complete serial sections of rat brains on postnatal day 0 to 2, which pretreated with methylazoxymethanol acetate on embryonic day 15. At birth, massive cellular clusters were found under the white matter of the cerebral cortex and then, a part of these clusters entered into the hippocampal CA1 sector on postnatal day 2. These ectopic cellular clusters in the CA1 were immunoreactive to anti‐calbindin antibody, suggesting that the origin of these cellular clusters is equivalent to that of the cortical layer II/III neurons. Next, we injected FluoroGold into the lateral septal nucleus to examine hippocampo‐septal projection. FluoroGold‐labeled neurons were scattered in the ectopic cellular cluster, implying that CA1 pyramidal neurons project normally to the lateral septal nucleus. In conclusion, a majority of neurons found in the ectopic cellular cluster caused by prenatal methylazoxymethanol treatment is derived from cortical neurons, and some intrinsic pyramidal neurons in the CA1 of hippocampus are scattered throughout the ectopic cellular cluster.
A common variant associated with asthma, interleukin 13 R130Q, promotes the production of IgE
Authors: Chu Y. , Hua L. , Liu Q. , Bao Y. 
Published: February 2012

SummaryInterleukin (IL)‐13 plays an important role in the pathogenesis of asthma. A polymorphic variant of human IL‐13 R130Q, results in substitution of an arginine with a glutamine was shown to be associated with asthma in Chinese Han nationality. We examined the functional consequences of this variant in vitro to investigate whether this variant enhanced functional activity compared with wild type IL‐13. The wild‐type and mutant IL‐13 genes were amplified from the plasmid of pET22b‐hIL‐13 by PCR and site‐directed mutagenesis PCR. Both the PCR product and the vector pET28a(+) were digested by the NdeI and BamHI. Then the PCR product was cloned in the prokaryotic expression vector of pET28a(+). The plasmids were constructed and transformed into E. coli BL21(DE3).The positive clones were selected, and tested by sequencing. Peripheral blood mononuclear cells (PBMCs) from healthy participants were isolated and cultured with increasing concentrations of recombinant WT IL‐13 and IL‐13 R130Q. IgE was detected with ELISA kit in the supernatants. Recombinant WT IL‐13 and IL‐13 R130Q were successfully expressed into the prokaryotic expression system and their biological activity was consistent with standard protein. Our results show that IL‐13 R130Q is more active than WT IL‐13 in inducing hydrocortisone‐dependent IgE synthesis. There were statistical significances between them. IgE induction by physiologic concentrations was obviously increased. IL‐13 R130Q has increased activity compared with wild type IL‐13 in vitro. And IL‐13 R130Q may be used for new target of asthma for diagnosis and therapy in the future.
Association of polymorphisms in interleukin‐18 and interleukin‐28B with Hepatitis B recurrence after liver transplantation in Chinese Han population
Authors: Li Y. , Shi Y. , Chen J. , Cai B. , Ying B. , Wang L. 
Published: February 2012

SummaryInterleukin‐18 (IL‐18) is a potent proinflammatory cytokine, which can promote hepatitis B virus clearance. The latest studies find that genetic polymorphisms near the IL‐28B gene are strongly associated with sustained viral response and spontaneous viral clearance in patients with chronically infected hepatitis C and hepatitis B. We investigated the effect of rs187238 and rs1946518 in IL‐18 gene and rs8099917 in IL‐28B gene on HBV recurrence in liver transplant patients. A total of 200 liver transplant recipients and relevant donors were enrolled in this study. The patients’ mean follow‐up was 39 month (range 10–65 month). All liver transplant recipients were in a stable stage. The total recipients (n = 200) were divided into end‐stage liver disease secondary to hepatitis B (n = 140) and end‐stage liver disease secondary to other diseases (n = 60) before transplantation. Recipients (n = 140) with hepatitis B before transplantation were defined to nonHBV recurrence group (n = 119) or HBV recurrence group (n = 21), which was positive for HBsAg or elevatory in HBV DNA (>2.0 × 102 IU mL−1) after transplantation. For the recipients (n = 140) had hepatitis B before transplantation, we studied the single‐nucleotide polymorphisms (SNPs) of IL‐18 gene (rs187238 and rs1946518) and IL‐28B gene (rs8099917) by high‐resolution melting (HRM) curve analysis. The serum levels of IL‐18 and IFN‐γ were tested by ELISA. The serums levels of IFN‐γ were lower in HBV recurrence group than that in nonHBV recurrence group (P < 0.01). The genotype of IL‐28B gene rs8099917 was associated with alanine aminotransferase (ALT) levels and aspartate aminotransferase (AST) levels in HBV‐related liver transplant recipients (n = 140). The recipients with allele G (GG+GT) had higher ALT and AST levels (P < 0.05). No association was found between IL‐18 gene and IL‐28B gene polymorphisms with HBV recurrence in the liver transplant recipients or the donors. We identified that the IFN‐γ was a protective factor of HBV recurrence after liver transplantation. The allele G of rs8099917 was associated with hepatitis B‐related hepatocytes injury. The rs8099917 G allele subgroup should reinforce antiviral therapy.
Combined Churg–Strauss syndrome and allergic bronchopulmonary aspergillosis – case report and review of the literature
Authors: Ren Shaohua 
Published: February 2012

AbstractA rare case of combined Churg–Strauss syndrome (CSS) and allergic bronchopulmonary aspergillosis (ABPA) was presented. A 41‐year‐old woman was diagnosed with CSS based upon asthma, eosinophilia (23%), chest radiographic findings, paranasal sinusitis, peripheral neuropathy and positive p‐ anti‐neutrophil cytoplasmic antibodies (pANCA). The diagnosis of ABPA was established on the pathological findings of allegic mucin impaction and fungal hyphae on lung biopsy. It was further proved by positive serum IgE and IgG antibodies specific to afumigatus. The clinical investigation features were reviewed in the patients with combined CSS and ABPA. All patients had the time sequence of the development of CSS after ABPA uniformly, suggesting immunopathogenesis involving the emergence of CSS. The role of lung biopsy in the diagnosis of the condition was emphasized.Please cite this paper as: Ren S. Combined Churg–Strauss syndrome and allergic bronchopulmonary aspergillosis – case report and review of the literature. Clin Respir J 2013; 7: e6–e10.